Pharmacies for the Pharmacists—Ukrainian Fears and Polish Experiences
Abstract
:1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Gross, M.; Volmer, D. Restrictions to Pharmacy Ownership and Vertical Integration in Estonia—Perception of Different Stakeholders. Pharmacy 2016, 4, 18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wisell, K.; Winblad, U.; Sporrong, S.K. Reregulation of the Swedish pharmacy sector—A qualitative content analysis of the political rationale. Health Policy 2015, 119, 648–653. [Google Scholar] [CrossRef] [PubMed]
- Blouin, R.A.; Adams, M.L. The Role of the Pharmacist in Health Care Expanding and Evolving. N. C. Med. J. 2017, 78, 165–167. [Google Scholar] [PubMed] [Green Version]
- Świeczkowski, D.; Merks, P.; Cwalina, N.; Jaguszewski, M.J. Development of Pharmacy Practice in European Countries—The Polish Perspective. Pharmacy 2017, 5, 43. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zaprutko, T.; Kopciuch, D.; Kus, K.; Merks, P.; Nowicka, M.; Augustyniak, I.; Nowakowska, E. Affordability of medicines in the European Union. PLoS ONE 2017, 12, e0172753. [Google Scholar] [CrossRef] [PubMed]
- Vogler, S.; Kilpatrick, K.; Babar, Z.-U.-D. Analysis of Medicine Prices in New Zealand and 16 European Countries. Value In Health 2015, 18, 484–492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martins, L.; Queirós, S. Competition among pharmacies and the typology of services delivered: The Portuguese case. Health Policy 2015, 119, 640–647. [Google Scholar] [CrossRef] [PubMed]
- Vogler, S.; Habimana, K.; Arts, D. Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries. Health Policy 2014, 117, 311–327. [Google Scholar] [CrossRef] [PubMed]
- Heinsohn, J.G.; Flessa, S. Competition in the German pharmacy market: An empirical analysis. BMC Health Serv. Res. 2013, 13, 407. [Google Scholar] [CrossRef] [PubMed]
- Lluch, M.; Kanavos, P. Impact of regulation of Community Pharmacies on efficiency, access and equity. Evidence from the UK and Spain. Health Policy 2010, 95, 245–254. [Google Scholar] [CrossRef] [PubMed]
- Vogler, S.; Arts, D.; Sandberger, K. Impact of Pharmacy Deregulation and Regulation in European Countries; Gesundheit Österreich GmbH: Vienna, Austria, 2012; ISBN 978-3-85159-163-7. [Google Scholar]
- Poland – More about pharmacy. EPhEU – Employed Community Pharmacists in Europe. Available online: https://epheu.eu/ (accessed on 3 January 2020).
- Trend Spadkowy Trwa, Ale z Mniejszym Impetem—Finanse i Zarządzanie. Available online: http://www.rynekaptek.pl/marketing-i-zarzadzanie/trend-spadkowy-trwa-ale-z-mniejszym-impetem,31753.html (accessed on 28 May 2019).
- Инφpacтpyктypa aптeчнoгo pитeйлa: нa пopoгe измeнeний | Eжeнeдeльник AПTEKA. Available online: https://www.apteka.ua/article/487942 (accessed on 4 February 2020).
- All pharmacy kiosks to close in Ukrainian cities — 20 July 2011. Available online: https://www.kyivpost.com/article/content/business/all-pharmacy-kiosks-to-close-in-ukrainian-cities-109016.html (accessed on 25 May 2019).
- Pharmaceutical Market of Ukraine: Realities and Perspectives. Available online: https://ldaily.ua/en/pharmaceutical-market-of-ukraine-realities-and-perspectives.html (accessed on 28 May 2019).
- 40% of Ukrainian Pharmacy Market Accounted for by 20 Largest Pharmacy Chains –Pharma & Healthcare Market in CEE & CIS—PMR. Available online: http://ceepharma-sphinx.pmr-www.nazwa.pl/news/259822/40-of-ukrainian-pharmacy-market-accounted-for-by-20-largest-pharmacy-chains (accessed on 2 April 2019).
- Rynek apteczny w Polsce. Available online: https://grantthornton.pl/wp-content/uploads/2019/02/Rynek-apteczny-w-Polsce-RAPORT-Grant-Thornon-13-02-2019.pdf (accessed on 3 February 2020).
- Zaprutko, T.; Kopciuch, D.; Paczkowska, A.; Sawicka, D.; Stachowiak, Z.; Bogdaniec, P.; Kus, K.; Nowakowska, E. Access to vaccination in the Greater Poland (Poland). Acta Poloniae Pharm. Drug. Res. 2019, 76, 195–201. [Google Scholar] [CrossRef]
- Die Apotheken. Zahlen, Daten, Fakten. Available online: https://www.abda.de/fileadmin/user_upload/assets/ZDF/ZDF_2018/ABDA_ZDF_2018_Brosch.pdf (accessed on 3 February 2020).
- Gellad, W.F.; Choudhry, N.K.; Friedberg, M.W.; Brookhart, M.A.; Haas, J.S.; Shrank, W.H. Variation in Drug Prices at Pharmacies: Are Prices Higher in Poorer Areas? Health Serv. Res. 2009, 44, 606–617. [Google Scholar] [CrossRef] [PubMed]
- Zaprutko, T.; Koligat, D.; Michalak, M.; Wieczorek, M.; Józiak, M.; Ratajczak, M.; Szydłowska, K.; Miazek, J.; Kus, K.; Nowakowska, E. Misuse of OTC drugs in Poland. Health Policy 2016, 120, 875–881. [Google Scholar] [CrossRef] [PubMed]
- Lakić, D.; Stević, I.; Odalović, M.; Vezmar-Kovačević, S.; Tadić, I. Patients’ willingness to pay for cognitive pharmacist services in community pharmacies. Croat. Med. J. 2017, 58, 364–371. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jaber, D.; Aburuz, S.; Hammad, E.A.; El-Refae, H.; Basheti, I.A. Patients’ attitude and willingness to pay for pharmaceutical care: An international message from a developing country. Res. Social. Adm. Pharm. 2018, 15, 1177–1182. [Google Scholar] [CrossRef] [PubMed]
- De Souza Cazarim, M.; Pereira, L.R.L. Cost-effectiveness analysis of pharmaceutical care for hypertensive patients from the perspective of the public health system in Brazil. PLoS ONE 2018, 13, e0193567. [Google Scholar]
- Bojke, C.; Philips, Z.; Sculpher, M.; Campion, P.; Chrystyn, H.; Coulton, S.; Cross, B.; Morton, V.; Richmond, S.; Farrin, A.; et al. Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings. Br. J. Gen. Pract. 2010, 60, e20–e27. [Google Scholar]
- Zaprutko, T.; Göder, R.; Kus, K.; Rakhman, L.; Bilobryvka, R.; Nowakowska, E. The Cost of Inpatient Care of Schizophrenia and Treatment Schedules Used in German Academic Center: Kiel. Psychiatr. Q. 2016, 87, 595–603. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Question | Question Content | Possible Answers |
---|---|---|
1 # | Did you fear the increase in the prices of pharmaceuticals as a result of the act “pharmacy for the pharmacist”? | Agree/disagree |
2 # | Did you fear reducing access to medicinal products as a result of geographical and demographic regulations as a result of the act “pharmacy for the pharmacist”? | Agree/disagree |
3 # | Were you afraid of the monthly turnover of the pharmacy reducing as a result of the introduction of the act “pharmacy for the pharmacist”? | Agree/disagree |
4 # | Were you afraid of the number of pharmacies reducing as a result of the introduction of the act “pharmacy for the pharmacist”? | Agree/disagree |
5 * | Do you think that the act “pharmacy for the pharmacist” may lead to the development of pharmaceutical care and improve the quality of pharmaceutical services provided by the pharmacy? | Agree/disagree |
6 ^ | Which of the problem listed above was found in market realities as a consequence of the act “pharmacy for the pharmacist”? |
|
Type of Pharmacy | Location | |||||||
---|---|---|---|---|---|---|---|---|
Individual | Mini-Chain 2–4 Pharmacies | Chain with 5 to 15 Pharmacies | Chain with >15 Pharmacies | Country | Town <20 Thousand Citizens | City up to 100 Thousand Citizens | City Inhabited by >100 Thousand Citizens | |
Poland | 27.14% (n = 114) | 23.33% (n = 98) | 21.67% (n = 91) | 27.86% (n = 117) | 5.71% (n = 24) | 19.05% (n = 80) | 30.95% (n = 130) | 44.29% (n = 186) |
Ukraine | 19.6% (n = 318) | 18.7% (n = 304) | 19.4% (n = 314) | 42.3% (n = 687) | 10.8% (n = 175) | 18.3% (n = 297) | 19.6% (n = 319) | 51.3% (n = 832) |
Question 1 | Question 2 | Question 3 | Question 4 | Question 5 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Agree | Disagree | p | Agree | Disagree | p | Agree | Disagree | p | Agree | Disagree | p | Agree | Disagree | p | |
Poland | 21.4% (n = 90) | 78.6% (n = 330) | p < 0 | 12.6% (n = 53) | 87.4% (n = 367) | p < 0 | 13.8% (n = 58) | 86.2% (n = 362) | p < 0 | 35% (n = 147) | 65% (n = 273) | p = 0.0056 | 57.6% (n = 242) | 42.4% (n = 178) | p = 0.0178 |
Ukraine | 76.8% (n = 1246) | 23.2% (n = 377) | 59.5% (n = 965) | 40.5% (n = 658) | 61.2% (n = 994) | 38.8% (n = 629) | 42.5% (n = 689) | 57.5% (n = 934) | 51.1% (n = 830) | 48.9% (n = 793) |
Type of Pharmacy | Location | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Individual | Mini-Chain 2-4 Pharmacies | Chain with 5 to 15 Pharmacies | Chain with > 15 Pharmacies | Country | Town < 20 Thousand Citizens | City up to 100 Thousand Citizens | City Inhabited by > 100 Thousand Citizens | |||
Poland | Q1 | agree | 19.30% (n = 22) | 19.30% (n = 18) | 18.68% (n = 17) | 28.21% (n = 33) | 41.67% (n = 10) | 22.50% (n = 18) | 16.15% (n = 21) | 22.04% (n = 41) * |
disagree | 80.70% * (n = 92) p < 0.0001 | 81.63% * (n = 80) p < 0.0001 | 81.32% * (n = 74) p < 0.0001 | 71.79% * (n = 84) p < 0.0001 | 58.33% (n = 14) p = 0.4208 | 77.50% * (n = 62) p < 0.0001 | 83.85% * (n = 109) p < 0.0001 | 77.96% (n = 145) p < 0.0001 | ||
p | NS | p = 0.0443 | ||||||||
Q2 | agree | 5.26% (n = 6) | 11.22% (n = 11) | 15.38% (n = 14) | 18.80% (n = 22) | 8.33% (n = 2) | 11.25% (n = 9) | 13.08% (n = 17) | 13.44% (n = 25) | |
disagree | 94.74% * (n = 108) p < 0.0001 | 88.78% * (n = 87) p < 0.0001 | 84.62% * (n = 77) p < 0.0001 | 81.20% * (n = 95) p < 0.0001 | 91.67% (n = 22) NS | 88.75% (n = 71) NS | 86.92% (n = 113) NS | 86.56% (n = 161) NS | ||
p | p = 0.0151 | NS | ||||||||
Q3 | agree | 5.26% (n = 6) | 12.24% (n = 12) | 12.09% (n = 11) | 24.79% (n = 29) | 8.33% (n = 2) | 7.50% (n = 6) | 14.62% (n = 19) | 16.67% (n = 31) | |
disagree | 94.74% * (n = 108) p < 0.0001 | 87.76% * (n = 86) p < 0.0001 | 87.91% * (n = 80) p < 0.0001 | 75.21% * (n = 88) p < 0.0001 | 91.67% (n = 22) NS | 92.50% (n = 74) NS | 85.38% (n = 111) NS | 83.33% (n = 155) NS | ||
p | p = 0.0002 | NS | ||||||||
Q4 | agree | 26.32% (n = 30) | 31.63% (n = 31) | 30.77% (n = 28) | 49.57% (n = 58) | 16.67% (n = 4) | 33.75% (n = 27) | 36.92% (n = 48) | 36.56% (n = 68) | |
disagree | 73.68% * (n = 84) p < 0.0001 | 68.37% * (n = 67) p < 0.0001 | 69.23% * (n = 63) p < 0.0001 | 50.43% * (n = 59) p < 0.0001 | 83.33% (n = 20) NS | 66.25% (n = 53) NS | 63.08% (n = 82) NS | 63.44% (n = 118) NS | ||
p | p = 0.0012 | NS | ||||||||
Q5 | agree | 68.42% (n = 78) | 56.12% (n = 55) | 65.93% (n = 60) | 41.88% (n = 49) | 50.0% (n = 12) | 58.75% (n = 47) | 56.15% (n = 73) | 59.14% (n = 110) | |
disagree | 31.58% * (n = 43) p = 0.0001 | 43.88% (n = 43) p = 0.2322 | 34.07% * (n = 31) p = 0.0038 | 58.12% (n = 68) p = 0.0829 | 50.0% (n = 12) NS | 41.25% (n = 33) NS | 43.85% (n = 57) NS | 40.86% (n = 76) NS | ||
p | p = 0.0002 | NS | ||||||||
Ukraine | Q1 | agree | 76.73% (n = 273) | 83.88% (n = 255) | 50.96% (n = 160) | 85.44% (n = 587) | 96.00% (n = 168) | 85.86% (n = 255) | 89.97% (n = 287) | 64.42% (n = 536) |
disagree | 23.27% * (n = 74) p < 0.0001 | 16.12% * (n = 49) p < 0.0001 | 49.04% (n = 154) p = 0.7337 | 14.56% * (n = 100) p < 0.0001 | 4.00% * (n = 7) p < 0.0001 | 14.14% * (n = 42) p < 0.0001 | 10.03% * (n = 32) p < 0.0001 | 35.58% * (n = 296) p < 0.0001 | ||
p | p < 0.0001 | p < 0.0001 | ||||||||
Q2 | agree | 58.18% (n = 185) | 57.89% (n = 176) | 41.40% (n = 130) | 69.00% (n = 474) | 80.57% (n = 141) | 64.98% (n = 193) | 73.04% (n = 233) | 47.84% (n = 398) | |
disagree | 41.82% * (n = 133) p = 0.0040 | 42.11% * (n = 128) p = 0.0066 | 58.60% * (n = 184) p = 0.0027 | 31.0% * (n = 213) p < 0.0001 | 19.43% * (n = 34) p < 0.0001 | 35.02% * (n = 104) p < 0.0001 | 26.96% * (n = 86) p < 0.0001 | 52.16% (n = 434) p = 0.2132 | ||
p | p < 0.0001 | p < 0.0001 | ||||||||
Q3 | agree | 53.46% (n = 170) | 70.07% (n = 213) | 37.26% (n = 117) | 71.91% (n = 494) | 81.14% (n = 142) | 64.31% (n = 191) | 74.61% (n = 238) | 50.84% (n = 423) | |
disagree | 46.54% (n = 148) p = 0.2183 | 29.93% * (n = 91) p < 0.0001 | 62.74% * (n = 197) p < 0.0001 | 28.09% * (n = 193) p < 0.0001 | 18.86% * (n = 33) p < 0.0001 | 35.69% * (n = 106) p < 0.0001 | 25.39% * (n = 81) p < 0.0001 | 49.16% (n = 409) p = 0.6280 | ||
p | p < 0.0001 | p < 0.0001 | ||||||||
Q4 | agree | 38.99% (n = 124) | 35.53% (n = 108) | 27.39% (n = 86) | 54.00% (n = 371) | 47.43% (n = 83) | 45.45% (n = 135) | 55.17% (n = 176) | 35.46% (n = 295) | |
disagree | 61.01% * (n = 194) p < 0.0001 | 64.47% * (n = 196) p < 0.0001 | 72.61% * (n = 228) p < 0.0001 | 46.00% * (n = 316) p = 0.0366 | 52.57% (n = 92) p = 0.4971 | 54.55% (n = 162) p = 0,1183 | 44.83% (n = 143) p = 0.0662 | 64.54% * (n = 537) p < 0.0001 | ||
p | p < 0.0001 | p < 0.0001 | ||||||||
Q5 | agree | 52.20% (n = 166) | 55.92% (n = 170) | 67.20% (n = 211) | 41.19% (n = 283) | 38.86% (n = 68) | 51.85% (n = 154) | 44.51% (n = 142) | 56.01% (n = 466) | |
disagree | 47.80% (n = 152) p = 0.4331 | 44.08% (n = 134) p = 0.4020 | 32.80% * (n = 103) p < 0.0001 | 58.81% (n = 404) p < 0.0001 | 61.14% * (n = 107) p < 0.0001 | 48.15% (n = 143) p = 0.5247 | 55.49% (n = 177) p = 0.0512 | 43.99% * (n = 366) p = 0.0002 | ||
p | p < 0.0001 | p < 0.0001 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zaprutko, T.; Hromovyk, B.; Lesyk, R.; Lesyk, L.; Kremin, Y.; Kus, K.; Kopciuch, D.; Ratajczak, P.; Paczkowska, A.; Nowakowska, E. Pharmacies for the Pharmacists—Ukrainian Fears and Polish Experiences. Sci. Pharm. 2020, 88, 7. https://doi.org/10.3390/scipharm88010007
Zaprutko T, Hromovyk B, Lesyk R, Lesyk L, Kremin Y, Kus K, Kopciuch D, Ratajczak P, Paczkowska A, Nowakowska E. Pharmacies for the Pharmacists—Ukrainian Fears and Polish Experiences. Scientia Pharmaceutica. 2020; 88(1):7. https://doi.org/10.3390/scipharm88010007
Chicago/Turabian StyleZaprutko, Tomasz, Bohdan Hromovyk, Roman Lesyk, Lilia Lesyk, Yuliia Kremin, Krzysztof Kus, Dorota Kopciuch, Piotr Ratajczak, Anna Paczkowska, and Elżbieta Nowakowska. 2020. "Pharmacies for the Pharmacists—Ukrainian Fears and Polish Experiences" Scientia Pharmaceutica 88, no. 1: 7. https://doi.org/10.3390/scipharm88010007